Former Food and Drug Administration Commissioner Scott Gottlieb said the U.S. "may have a missed a window" to scale up production of coronavirus treatments, which "could have been an important bridge to a vaccine." On Tuesday, Gottlieb discussed the strategy of ratcheting up vaccine production even before federal approval to get a stockpile ready. He said the focus on vaccine development means less emphasis on a potential treatment known as monoclonal antibodies. The treatment, made of genetically engineered antibodies, is reportedly a promising method in fighting COVID-19, and two separate clinical trials are in progress. The speed has been focused on vaccines, though Gottlieb said the antibody treatment could serve as a "hedge in the event vaccines are delayed or don't work." Because of the slow progress, Gottlieb said, "we just don't have enough doses to realize that goal."
need to know now